Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × Priapism × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 4472 Neoplasms 3714 Prostatic Neoplasms 2181 Carcinoma, Non-Small-Cell Lung 1981 Colorectal Neoplasms 1833 Lung Neoplasms 1523 Multiple Myeloma 1287 Lymphoma 1267 Neoplasm Metastasis 1229 Leukemia, Myeloid, Acute 1212 Melanoma 1132 Pancreatic Neoplasms 1077 Leukemia 1072 Ovarian Neoplasms 1061 Lymphoma, Non-Hodgkin 994 Precursor Cell Lymphoblastic Leukemia-Lymphoma 952 Head and Neck Neoplasms 936 Leukemia, Lymphocytic, Chronic, B-Cell 872 Brain Neoplasms 800 Colonic Neoplasms 797 Lymphoma, Follicular 785 Stomach Neoplasms 766 Carcinoma, Hepatocellular 755 Recurrence 752 Glioblastoma 751 Rectal Neoplasms 683 Lymphoma, Large B-Cell, Diffuse 672 Uterine Cervical Neoplasms 640 Carcinoma, Renal Cell 623 Hodgkin Disease 617

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed

198 enrolled 18 charts 1 FDA

Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡